Steroid Use at 7 Weeks Post-Transplant for Graft Rejection

Treatment of Acute Rejection at 7 Weeks

The American College of Cardiology is not applicable here, however, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend corticosteroids as the first-line treatment for acute graft rejection at 7 weeks post-kidney transplant, and if the patient is not already on maintenance steroids, prednisone should be added or restored to the regimen 1
A kidney allograft biopsy should be performed before initiating rejection treatment unless the biopsy would substantially delay therapy, and at 7 weeks post-transplant, any unexplained rise in serum creatinine warrants biopsy to confirm rejection and rule out other causes like calcineurin inhibitor toxicity 1
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that high-dose intravenous methylprednisolone is not the only option, but corticosteroids are the recommended initial treatment for acute cellular rejection at any time point post-transplant, including 7 weeks 1

If the patient was not on maintenance prednisone at the time of rejection, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend adding or restoring maintenance prednisone to the immunosuppressive regimen, even if the patient was initially on a steroid-avoidance or early withdrawal protocol 1
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that prednisone should be continued rather than withdrawn if being used beyond the first week post-transplant 3, 4

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend using lymphocyte-depleting antibodies or OKT3 for acute cellular rejections that do not respond to corticosteroids, and these agents are also indicated for recurrent acute cellular rejections 1

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that steroid avoidance or early withdrawal is only appropriate for low immunologic risk patients who have NOT experienced rejection, and the occurrence of rejection at 7 weeks indicates the patient requires more intensive immunosuppression, not less 1, 3, 4

If serum creatinine has not returned to baseline after treatment of acute rejection, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest repeat biopsy, and adjust maintenance immunosuppression upward rather than continuing dose reduction strategies that were planned for rejection-free patients 1, 4

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend not continuing steroid-free protocols after a rejection episode, as the rejection itself indicates inadequate immunosuppression, and do not delay biopsy for prolonged periods when rejection is suspected, as early diagnosis and treatment improve outcomes 1
Ensure calcineurin inhibitor levels are therapeutic, as subtherapeutic tacrolimus levels may have contributed to the rejection episode 4